Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-β1-connective tissue growth factor signalling cascade.
1. Transforming growth factor-β1 (TGF-β1) and connective tissue growth factor (CTGF) are expressed in renal glomeruli, and contribute to the development of diabetic nephropathy. Recently, we showed that (pro)renin receptor (PRR) is upregulated in the kidneys of the streptozocin (STZ)-induced diabetes rat model. We hypothesized that in the presence of hyperglycaemia, increased renal PRR expression contributes to enhanced TGF-β1-CTGF signalling activity, leading to the development of diabetic kidney disease. 2. In vivo and in vitro studies were carried out in Sprague-Dawley rats and rat mesangial cells (RMC). PRR blockade was achieved in vivo by treating STZ induced diabetes rats with the handle region peptide (HRP) of prorenin and in vitro by HRP or PRR siRNA in RMC. Angiotensin AT1 receptor blockade was achieved by valsartan treatment. 3. Results showed that expression of PRR, TGF-β1 and CTGF were upregulated in diabetic kidneys and RMC exposed to high glucose. Glucose exposure also induced PRR phosphorylation, a process that was inhibited by HRP, valsartan or PRR siRNA. HRP and valsartan significantly attenuated renal TGF-β1 and CTGF expression in diabetic animals and high glucose treated RMC. Similar results were observed in high glucose exposed RMC in response to PRR siRNA. TGF-β receptor blockade decreased CTGF expression in RMC. Combined administration of valsartan and PRR siRNA showed further reduction of TGF-β1 and CTGF expression in RMC. 4. In conclusion, PRR contributes to kidney disease in diabetes through an enhanced TGF-β1-CTGF signalling cascade.
Department of Medicine, Division of Endocrinology & Metabolism, University of Virginia Health System, Charlottesville, VA 22908-1409, USA.
Jiqian
J
Huang
Luis C
LC
Matavelli
Helmy M
HM
Siragy
D000818:Animals; D055513:Connective Tissue Growth Factor / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000235:genetics / Q000378:metabolism*; D005947:Glucose / Q000378:metabolism / Q000494:pharmacology; D006943:Hyperglycemia / Q000378:metabolism; D008297:Male; D050527:Mesangial Cells / Q000187:drug effects / Q000378:metabolism; D009842:Oligopeptides / Q000235:genetics / Q000494:pharmacology; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D013777:Tetrazoles / Q000494:pharmacology; D053773:Transforming Growth Factor beta1 / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D015854:Up-Regulation; D014633:Valine / Q000031:analogs & derivatives / Q000494:pharmacology; D000068756:Valsartan; D000093342:Prorenin Receptor
D009842:Oligopeptides; D034741:RNA, Small Interfering; D044140:Receptor, Angiotensin, Type 1; D011956:Receptors, Cell Surface; D013777:Tetrazoles; D053773:Transforming Growth Factor beta1; C527127:handle-region peptide, rat; D055513:Connective Tissue Growth Factor; D000068756:Valsartan; D014633:Valine; D005947:Glucose; D000093342:Prorenin Receptor
J Clin Invest. 1994 Jun;93(6):2431-7
8200978
Curr Hypertens Rep. 2002 Oct;4(5):403-7
12217260
J Am Soc Nephrol. 2006 Sep;17(9):2495-503
16885412
Am J Physiol. 1994 Dec;267(6 Pt 2):F1094-01
7810696
Kidney Int. 1996 Dec;50(6):1897-903
8943472
Endocrinology. 2010 Jul;151(7):3317-25
20444941
Kidney Int Suppl. 1998 Dec;68:S41-5
9839282
J Am Soc Nephrol. 2007 Jun;18(6):1789-95
17494887
J Am Soc Nephrol. 2009 Sep;20(9):1997-2008
19628668
Biochem Biophys Res Commun. 2006 Jan 13;339(2):633-41
16310163
Biochem J. 2001 Oct 1;359(Pt 1):77-87
11563971
J Am Soc Nephrol. 2000 Jan;11(1):25-38
10616837
Hypertens Res. 2004 Feb;27(2):129-35
15005276
Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S134-8
11576939
Hypertension. 2004 May;43(5):1133-9
15007031
Hypertension. 2010 Jun;55(6):1454-60
20368504
Miner Electrolyte Metab. 1998;24(2-3):174-80
9525702
Hypertension. 2006 May;47(5):894-900
16585419
J Am Soc Nephrol. 2009 Apr;20(4):765-76
19297557
Kidney Int. 2006 Jan;69(1):105-13
16374430
Kidney Int. 2000 Oct;58(4):1389-99
11012874
J Clin Invest. 2002 Jun;109(11):1417-27
12045255
J Biol Chem. 1999 Feb 26;274(9):5830-4
10026205
Cell Growth Differ. 1996 Apr;7(4):469-80
9052988
Kidney Int. 1998 Oct;54(4):1390-1
9773681
Kidney Int. 2006 Mar;69(6):1064-72
16528256
Circ Res. 2010 Jul 9;107(1):30-4
20570919
J Clin Invest. 2004 Oct;114(8):1128-35
15489960
J Am Soc Nephrol. 2007 Jul;18(7):2054-61
17538189
J Am Soc Nephrol. 2008 Apr;19(4):743-8
18235083
Cytokine Growth Factor Rev. 1997 Sep;8(3):171-9
9462483
Hypertension. 1998 Jan;31(1 Pt 2):181-8
9453300
Am J Physiol Renal Physiol. 2004 Feb;286(2):F278-87
14583433
Exp Physiol. 2008 May;93(5):709-14
18192338
Hypertension. 2001 Sep;38(3 Pt 2):635-8
11566946
Science. 2010 Jan 22;327(5964):459-63
20093472
Hypertension. 2009 Aug;54(2):261-9
19546380
Clin Exp Pharmacol Physiol. 2010 Mar;37(3):277-82
19769609
Kidney Int. 1995 Dec;48(6):1818-27
8587241
Ren Fail. 2001 May-Jul;23(3-4):471-81
11499562
Endocrinology. 2009 Dec;150(12):5557-65
19861503
Hypertension. 2008 Mar;51(3):676-81
18212268
J Clin Invest. 1993 Sep;92(3):1366-72
7690779